search
Back to results

Impact of Metabolic Syndrome on Flu Vaccine Efficacy

Primary Purpose

Immune Deficiency, Metabolic Syndrome

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Influenza vaccine
Sponsored by
Rockefeller University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Immune Deficiency

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion criteria for the METABOLIC SYNDROME COHORT( Participants must have 3 or more of the following 5 risk factors):

  • Abdominal Obesity, given as a waist circumference: Men >102 cm (>40 in) Women > 88 cm (>35 in)
  • Triglycerides >150 mg/dl
  • HDL Cholesterol: Men < 40 mg/dl Women < 50 mg/dl
  • Blood Pressure >130/ >85 mm Hg - or controlled on antihypertensive medication
  • Fasting Glucose > 100 mg/dl

Inclusion criteria for the HEALTHY CONTROLS (Participants must have all of the requirements below) :

  • body mass index 18.5 - 25 kg/m2
  • HDL female > 50 mg/dL, male > 40 mg/dL
  • fasting glucose < 100 mg/dL
  • triglycerides <150 mg/dL,
  • waist circumference of a female < 88 cm, male < 102 cm)
  • - Blood pressure < or = to 120/80 (based on an average of 3 readings taken 5 minutes apart after the consent form has been signed)

Exclusion criteria :

  • Currently undergoing treatment for the metabolic syndrome
  • The average of 2 BP readings > 150/90 (based on 2 B/Ps taken at screening visit 1).
  • Hepatitis A, B and C
  • NSAIDs and/or Aspirin ingestion within the last 14 days
  • Self-reported history of any active autoimmune diseases
  • Self-reported ingestion of statins within the last 3 months
  • Self-reported antibiotic use within the last 3 months
  • Anti-inflammatory drugs including biologics and corticosteroids within last 3 months( nasal spray and topical applications are OK)or Omega 3 Fatty Acids.
  • Self-reported hx of cancer treatment within the last year
  • Allergy to eggs
  • History of Guillain-Barre syndrome
  • Pregnant ( determined by point of care testing at screening visit 1).
  • HIV positive
  • Self-reported history of flu vaccination within the past 3 months.
  • Any self-reported infection in the week of the visit except the first two visits (Screening visit 1 and Screening visit 2) and the last visit (Study visit #5) that could be rescheduled.
  • Any medical, psychological or social condition that, in the opinion of the Investigator, would jeopardize the health or well-being of the participant during any study procedures or the integrity of the data.

Study Population Description The population from which the groups will be selected are resident of New York City.

Sites / Locations

  • Rockefeller University

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Influenza vaccine in metabolic syndrome

Influenza vaccine in healthy controls

Arm Description

Influenza vaccine

Influenza vaccine

Outcomes

Primary Outcome Measures

Antibody Response D28
Measured by hemagglutination inhibition assay

Secondary Outcome Measures

Gene Expression Profiling D1
Analyze by RNA-seq
Gene Expression Profiling D28
Analyze by RNA-seq
Gene Expression Profiling D90
Analyze by RNA-seq
Antibody Response D90
Measured by hemagglutination inhibition assay

Full Information

First Posted
January 8, 2016
Last Updated
September 1, 2017
Sponsor
Rockefeller University
search

1. Study Identification

Unique Protocol Identification Number
NCT02653495
Brief Title
Impact of Metabolic Syndrome on Flu Vaccine Efficacy
Official Title
Impact of Metabolic Syndrome on Flu Vaccine Efficacy
Study Type
Interventional

2. Study Status

Record Verification Date
September 2017
Overall Recruitment Status
Terminated
Why Stopped
Target accrual not met
Study Start Date
January 2016 (undefined)
Primary Completion Date
March 2017 (Actual)
Study Completion Date
March 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Rockefeller University

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Metabolic syndrome (MetS) is a cluster of metabolic conditions associated with obesity that predispose individuals to coronary heart diseases and diabetes but obesity has been shown to increase the risks of other diseases like cancer and asthma. Studies have also shown that obesity increases the risk of severe influenza infection and associated death and reduces the efficacy of influenza vaccine in the obese population but yet, the molecular mechanisms have not been described. The investigators are thus hypothesizing that differences in the innate immune responses between individual with or without metabolic syndrome impact viral infection and vaccine outcome. The investigators will perform seasonal influenza vaccination in people with or without metabolic syndrome to determine if the late adaptive response assessed by antibodies titers is different between the two groups and correlates with the early immune response assessed by gene expression profile in whole blood cells. The project proposed by the investigators will contribute to a better understanding of the inflammatory phenotype associated with metabolic syndrome and establish for the first time if it affects the immune protection against infectious diseases and particularly against influenza virus infection. The results will be important to determine if the population affected by metabolic syndrome should receive anti-influenza treatment in priority in the context of a severe influenza epidemic.
Detailed Description
The development of industrialization with increased food consumption and sedentarity has given rise to an obesity pandemic, which affects up to 30% of the population in countries like US, these populations being at greater risk for cardiovascular diseases, and diabetes. More than obesity per se, visceral obesity is associated with metabolic diseases that cluster together and clinically defined metabolic syndrome. MetS comprises individuals with at least three of the 5 of the following factors: abdominal obesity, high blood triglycerides, low HDL ("good cholesterol"), high blood pressure and elevated fasting glucose. Metabolic syndrome is associated with a low-grade inflammation characterized by an infiltration of immune cells particularly in the adipose tissue, the liver and the pancreas that is thought to be responsible for the induction of insulin resistance. It is thought that obesity predisposes to other diseases such as cancer, asthma but only little attention has been given to infectious diseases. Studies have shown that obesity increases the risk of severe influenza infection and associated death and reduces the efficacy of influenza vaccine in the obese population but yet, the molecular mechanisms have not been described. Immune dysfunctions associated with obesity are suspected to play a major role but obesity is often associated with respiratory disorders that could directly explain the increased susceptibility to influenza infection. Also, metabolically healthy obesity is less associated with inflammation. Therefore, the investigators would like to focus particularly on metabolic syndrome, and determine how it influences immune response to viruses. The investigators are thus hypothesizing that differences in the innate immune responses between individual with or without metabolic syndrome impact viral infection and vaccine outcome. Recent studies involving complex biological analysis and computational modeling have shown that the ability of an individual to positively respond to influenza vaccine can be molecularly predicted by looking at markers in the blood cells. The investigators will perform seasonal influenza vaccination in people with or without metabolic syndrome to determine if the late adaptive response assessed by antibodies titers is different between the two groups and correlates with the early immune response assessed by gene expression profile in whole blood cells. Healthy nutritional habits along with increased physical activities should be best at preventing the development of metabolic syndrome but socio-economical issues are slowing the implementation of these changes. Therefore, as metabolic syndrome is raising public health concerns, it is important to understand why the metabolic syndrome affects susceptibility to diseases.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Immune Deficiency, Metabolic Syndrome

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
17 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Influenza vaccine in metabolic syndrome
Arm Type
Experimental
Arm Description
Influenza vaccine
Arm Title
Influenza vaccine in healthy controls
Arm Type
Experimental
Arm Description
Influenza vaccine
Intervention Type
Biological
Intervention Name(s)
Influenza vaccine
Intervention Description
Influenza vaccine administered intramuscularly (IM), 1 time only, on visit 3
Primary Outcome Measure Information:
Title
Antibody Response D28
Description
Measured by hemagglutination inhibition assay
Time Frame
28 days after vaccination compare to baseline (screening visit 1) pre-vaccination
Secondary Outcome Measure Information:
Title
Gene Expression Profiling D1
Description
Analyze by RNA-seq
Time Frame
1 day post-vaccination compare to baseline (gene expression screening visit #1 and study visit #1 D0 of vaccination)
Title
Gene Expression Profiling D28
Description
Analyze by RNA-seq
Time Frame
28 days post-vaccination compare to baseline (gene expression screening visit #1 and study visit #1 D0 of vaccination)
Title
Gene Expression Profiling D90
Description
Analyze by RNA-seq
Time Frame
90 days post-vaccination compare to baseline (gene expression screening visit #1 and study visit #1 D0 of vaccination)
Title
Antibody Response D90
Description
Measured by hemagglutination inhibition assay
Time Frame
90 days after vaccination compare to day 28

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria for the METABOLIC SYNDROME COHORT( Participants must have 3 or more of the following 5 risk factors): Abdominal Obesity, given as a waist circumference: Men >102 cm (>40 in) Women > 88 cm (>35 in) Triglycerides >150 mg/dl HDL Cholesterol: Men < 40 mg/dl Women < 50 mg/dl Blood Pressure >130/ >85 mm Hg - or controlled on antihypertensive medication Fasting Glucose > 100 mg/dl Inclusion criteria for the HEALTHY CONTROLS (Participants must have all of the requirements below) : body mass index 18.5 - 25 kg/m2 HDL female > 50 mg/dL, male > 40 mg/dL fasting glucose < 100 mg/dL triglycerides <150 mg/dL, waist circumference of a female < 88 cm, male < 102 cm) - Blood pressure < or = to 120/80 (based on an average of 3 readings taken 5 minutes apart after the consent form has been signed) Exclusion criteria : Currently undergoing treatment for the metabolic syndrome The average of 2 BP readings > 150/90 (based on 2 B/Ps taken at screening visit 1). Hepatitis A, B and C NSAIDs and/or Aspirin ingestion within the last 14 days Self-reported history of any active autoimmune diseases Self-reported ingestion of statins within the last 3 months Self-reported antibiotic use within the last 3 months Anti-inflammatory drugs including biologics and corticosteroids within last 3 months( nasal spray and topical applications are OK)or Omega 3 Fatty Acids. Self-reported hx of cancer treatment within the last year Allergy to eggs History of Guillain-Barre syndrome Pregnant ( determined by point of care testing at screening visit 1). HIV positive Self-reported history of flu vaccination within the past 3 months. Any self-reported infection in the week of the visit except the first two visits (Screening visit 1 and Screening visit 2) and the last visit (Study visit #5) that could be rescheduled. Any medical, psychological or social condition that, in the opinion of the Investigator, would jeopardize the health or well-being of the participant during any study procedures or the integrity of the data. Study Population Description The population from which the groups will be selected are resident of New York City.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ursula Andreo, PhD
Organizational Affiliation
The Rockefeller University Center for Clinical and Translational
Official's Role
Principal Investigator
Facility Information:
Facility Name
Rockefeller University
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Impact of Metabolic Syndrome on Flu Vaccine Efficacy

We'll reach out to this number within 24 hrs